 Home > Medical News > Latest Medical News > AbbVie's oral CGRP antagonist Qulipta receives FDA approval for preventive treatment of migraine

AbbVie's oral CGRP antagonist Qulipta receives FDA approval for preventive treatment of migraine

 Last Update: 2021-11-16
 Source: Internet
 Author: User

Tags

fentanyl adverse effects

bronchospasm treatment

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

CompilationTom Lee

Recently, AbbVie announced that the U.

The approval of this oral CGRP antagonist is supported by data from a strong clinical program that evaluated Qulipta's efficacy, safety, and tolerability in nearly 2,000 migraine patients who experienced an average of 4 to 14 days per month

In the pivotal multicenter, randomized, double-blind, placebo-controlled Phase III ADVANCE trial, compared with placebo, patients had a statistically significant decrease in the average number of migraine days per month, receiving 60 mg Qulipta within 12 weeks The number of days of headache decreased from baseline to 4.

In the trial, all doses of Qulipta group showed good tolerance

Migraine is a complex disease with recurrent episodes and usually incapacitates people.

Qulipta is an oral calcitonin gene-related peptide (CGRP) receptor antagonist (gepant), originally developed specifically for the preventive treatment of migraine

The approved Qulipta includes three doses of 10 mg, 30 mg and 60 mg, and is expected to be on the market in early October 2021

Reference source:

FDA Approves QULIPTA™ (atogepant), the First and Only Oral CGRP Receptor Antagonist specifically Developed for the Preventive Treatment of Migraine

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.